Obviousness

Obviousness Analysis of US Patent 11857333 under 35 U.S.C. § 103

This analysis assesses the obviousness of US Patent 11857333 ("the '333 patent") under 35 U.S.C. § 103, considering prior art available as of its priority date of November 4, 2005. The level of ordinary skill in the art (POSITA) at that time would encompass individuals with expertise in biomedical engineering, sleep medicine, signal processing, and medical device design. Such a POSITA would be familiar with polysomnography (PSG), home sleep testing (HST), continuous positive airway pressure (CPAP) and positive airway pressure (PAP) devices, data acquisition systems, remote monitoring, and basic artificial intelligence/machine learning applications in medicine.

The '333 patent identifies several limitations of the prior art, specifically stating that no devices on the market could:

• Adjust gas flow based on a comprehensive evaluation of a subject's physiological state.
• Use a rich data set to predict/detect apnea and provide appropriate treatment.
• Employ a rich data set over single or multiple nights for optimal CPAP/PAP titration.
• Automatically adjust a treatment device based on physiological signals.
• Be used for CPAP/PAP titration in the subject's home.

These stated shortcomings represent problems that a POSITA would have been motivated to address using existing technologies.

I. Scope and Content of the Prior Art

Based on the patent's own statements and additional searches for prior art around the 2005 priority date, the following was known:

1. Home Sleep Testing (HST) Devices: By the mid-1990s, HST devices were evolving. Early devices measured limited parameters, but by the mid-2000s, more sophisticated HST devices were portable and capable of measuring multiple physiological parameters such as SpO2, pulse rate, oral/nasal airflow, respiratory effort, and body position, storing data, and offering improved user-friendliness for home use. While often lacking EEG, these devices provided multi-channel data. For example, WO 2006/082589 A2 (priority February 2005) describes a multi-sensor unit for home use, including a photoplethysmographic sensor for blood oxygen and a sensor for respiratory motion, capable of diagnosing apnea type and assessing stress response.
2. Automatic CPAP (Auto-CPAP) Systems: Auto-CPAP devices were available and designed to automatically and continuously adjust nasal pressure based on sensed parameters, primarily airflow, to maintain airway patency during sleep. These systems used feedback from integrated sensors (e.g., pneumotachographs, pressure sensors) to adapt pressure to variations in breathing patterns, body position, and sleep stages. Studies comparing auto-CPAP to manual titration for home use were also being conducted by 2005, suggesting auto-CPAP as a reliable alternative for determining therapeutic pressure in the home.
3. Remote Patient Monitoring (RPM): The underlying technology for remote monitoring of patients was well-established. Transmitting physiological signals (e.g., EKGs) over telephone lines dated back to 1967, and the internet's development in the 1990s significantly expanded telemedicine capabilities, enabling electronic data transmission. US5357427A (1994) described a system for remote monitoring of high-risk patients using artificial intelligence and telephone lines. US20080269571A1 (application filed 2004) further describes multi-user remote health monitoring systems capable of collecting and transmitting data via communication networks.
4. Artificial Intelligence (AI) and Machine Learning (ML) in Medical Devices: The application of AI, particularly artificial neural networks (ANNs), in medical diagnostics and device control was known and developing rapidly since the 1980s. By 2000, discussions included ANNs for medical devices that could "learn" to support care providers and improve diagnostic accuracy. Machine learning algorithms were used to analyze medical datasets from early on.
5. Signal Processing Techniques: Standard signal processing algorithms, including Fourier Transforms, Short-Time Fourier Transforms (STFT), wavelet analysis, and various statistical methods, were well-known and applied in biomedical signal analysis for extracting meaningful information from physiological data.
6. Integrated Diagnostic and Treatment Concepts: While not explicitly detailed, US Patent 8,172,766 B1, from which the '333 patent claims priority (via its application US11/266,899), is titled "Apparatus and method for diagnosing and treating sleep disorders." This indicates that the fundamental concept of an integrated system for both diagnosis and treatment of sleep disorders was part of the common inventive landscape originating from the same assignees around the priority date.

II. Motivation to Combine Prior Art References

A POSITA in 2005 would have been motivated to combine the aforementioned prior art elements for several compelling reasons:

• Improved Treatment Efficacy: The recognized limitations of simple auto-PAP devices (relying on single physiological variables) created a strong motivation to integrate richer diagnostic data (e.g., from multi-sensor HST devices) to provide more precise and effective therapy.
• Enhanced Patient Convenience and Compliance: The shift towards home-based sleep studies and therapy was driven by the desire for more comfortable, less intrusive, and less expensive options compared to in-lab PSG. Integrating multi-sensor diagnosis with automated treatment in a portable, home-friendly system would directly address this. Wireless communication was already recognized for improving patient mobility and reducing restrictions.
• Remote Management and Efficiency: The advancements in telemedicine and remote monitoring provided a clear motivation to allow clinicians to remotely review diagnostic data and adjust treatment parameters, thereby optimizing therapy without requiring frequent in-person visits.
• Leveraging Computational Power and AI: The growing capabilities of microprocessors and the emerging understanding of AI/ML applications in medicine would have motivated a POSITA to develop "smarter" devices. Specifically, using rich diagnostic data to "train" a treatment device's simpler sensors (e.g., via neural networks) would be a logical step to overcome the limitations of rudimentary auto-adjustment algorithms.

III. Obviousness Arguments for Representative Claims

Given the motivations and available prior art, many claims of US11857333B1 would have been obvious to a POSITA by November 4, 2005.

1. Claim 1: Integrated System with Sensor and CPAP
Claim 1 describes a sleep apnea treatment system with a data acquisition system (at least one sensor, electronic component for signal reception and retransmission/transmission) and a CPAP device with an electrical connection to receive the signal, where the CPAP is adjusted based on this signal.

• Combination: US8172766B1 (or its application) inherently suggests an integrated diagnosis and treatment system for sleep disorders. A POSITA would combine the multi-sensor diagnostic capabilities (e.g., from WO 2006/082589 A2, US6062216A, or US5245995A, which describe various physiological sensors and data acquisition) with an existing auto-CPAP device (e.g., US5645053A, US5245995A) that already uses electrical signals from internal sensors (e.g., airflow, pressure) for adjustment.
• Motivation: The motivation would be to enhance the auto-CPAP's effectiveness by providing it with additional or more refined physiological input from external diagnostic sensors, moving beyond the single-variable feedback prevalent in existing auto-CPAP systems.

2. Claim 11: Wireless Multi-Sensor System and CPAP Adjustment
Claim 11 specifies a sleep apnea treatment system with a data acquisition system having two or more sensors, wirelessly transmitting signals, and a CPAP device with a wireless receiver for adjustment based on these signals.

• Combination: A POSITA would combine known multi-sensor HST devices (e.g., those described in WO 2006/082589 A2 which used multiple sensors for home monitoring, or the evolving HST devices mentioned in "HST: Past, Present, & Future") with established wireless communication technologies for medical data (e.g., as widely available by 2005, and exemplified by remote patient monitoring systems). This wirelessly transmitted multi-sensor data would then be used to control an auto-CPAP device (e.g., US5645053A) which already incorporated automated adjustment logic.
• Motivation: The primary motivation would be to improve patient comfort, mobility, and compliance for home-based diagnosis and titration by eliminating physical tethers, a recognized benefit of wireless systems. The ability of auto-CPAPs to adjust based on physiological data was already known.

3. Claim 12: Remote Monitoring and Command for CPAP Adjustment
Claim 12 describes a system with a data acquisition system that processes and transmits signals, a CPAP device, and a remote monitoring station that receives the processed signal and transmits a command signal to the CPAP for adjustment.

• Combination: This combines a data acquisition system with processing and transmission capabilities (as in US8172766B1, or multi-sensor systems like WO 2006/082589 A2) with a remote patient monitoring station (e.g., US5357427A, US20080269571A1). The remote station's ability to receive and process data, coupled with the known adjustability of auto-CPAP devices (e.g., US5645053A), makes the addition of transmitting a command signal for remote adjustment a straightforward and obvious extension of existing telemedicine principles.
• Motivation: The motivation is to enable clinicians to remotely oversee and fine-tune CPAP therapy, particularly during home titration, thereby improving accessibility, efficiency, and clinical outcomes by allowing expert intervention without requiring in-person visits.

4. Claim 17: Method of Treatment with Periodic Adjustment
Claim 17 outlines a method including attaching a sensor, connecting it to a data acquisition system, collecting data during sleep, transmitting (raw or processed) signals to a PAP/CPAP device, and periodically adjusting the gas flow based on the signal.

• Combination: The steps are a direct application of combining a multi-sensor diagnostic method (e.g., comprehensive HST as described in "HST: Past, Present, & Future" or the system in WO 2006/082589 A2) with the automated treatment capabilities of a PAP/CPAP device (e.g., US5645053A). The periodic adjustment is inherent in any closed-loop control system, such as auto-CPAP, which continuously adapts to patient needs.
• Motivation: To improve the efficacy and adaptability of PAP/CPAP therapy by using real-time or near real-time physiological feedback, making the treatment more responsive to the patient's condition throughout the sleep period. This method also aligns with the push for more convenient, home-based titration.

5. "Training" the Treatment Device (as described in the specification)
The specification describes using "robust data collected during the titration with the diagnostic device" to "teach or train the treatment device to correlate the more robust data from the diagnostic device to limited sensor signatures from the PAP or CPAP device to allow for more accurate control," potentially using a neural network.

• Combination: This concept would be obvious by combining multi-sensor diagnostic systems capable of collecting "rich" data (e.g., WO 2006/082589 A2, US8172766B1, or advanced HST devices) with the known application of artificial intelligence and neural networks in medical devices for diagnosis and learning (as described in articles from 2000-2005, and in remote monitoring systems like US5357427A), and applying these to control an auto-CPAP device (e.g., US5645053A).
• Motivation: A POSITA would be motivated to apply existing machine learning techniques to a known problem: improving the accuracy and sophistication of auto-CPAP algorithms. By "training" a CPAP device to understand the relationship between a comprehensive diagnostic dataset and its own more limited sensor readings, the device could achieve more precise and personalized therapy, addressing the limitation of relying on a "single physiological variable" as described in the '333 patent itself.

In conclusion, the various independent claims of US Patent 11857333, covering an integrated sleep diagnostic and therapeutic system and method, would have been obvious to a person of ordinary skill in the art by the priority date of November 4, 2005. The motivation to combine existing technologies such as multi-sensor home sleep testing, auto-CPAP devices, remote patient monitoring, and nascent AI/machine learning in medical applications was driven by clear desires to improve treatment efficacy, patient convenience, remote management, and the intelligence of automated therapeutic devices.